title: Nuclear imaging of bone tumors: FDG-PET.
abstract: Positron emission tomography (PET) has become a very useful adjunct to anatomic imaging techniques, because it can provide an in vivo method for quantifying functional metabolism in normal and diseased tissues. Clinical trials with [(18)F] 2-deoxy-2-fluoro-D-glucose (FDG), the most commonly used radiolabeled tracer for PET imaging, has demonstrated increased accumulation of FDG in cancer tissue. FDG-PET is now widely used for the detection, differentiation, grading, staging, and monitoring of various neoplasms. However, the significance of FDG-PET in such evaluations of primary bone tumors and tumor-like lesions has not been extensively elucidated. In this article, we present recent advances in FDG-PET studies for evaluating primary bone tumors and tumor-like lesions.
authors.affiliation: Department of Diagnostic Radiology, Gunma University School of Medicine, 3--39--22 Showa-machi, Maebashi 371--8511 Japan.
authors.forename: J
authors.initials: J
authors.lastname: Aoki
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: K
authors.initials: K
authors.lastname: Tomiyoshi
authors.forename: T
authors.initials: T
authors.lastname: Shinozaki
authors.forename: H
authors.initials: H
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Takagishi
authors.forename: K
authors.initials: K
authors.lastname: Endo
mesh_terms: D001859:Bone Neoplasms / Q000000981:diagnostic imaging*; D003937:Diagnosis, Differential; D019788:Fluorodeoxyglucose F18; D006801:Humans; D019275:Radiopharmaceuticals; D012509:Sarcoma / Q000000981:diagnostic imaging; D014055:Tomography, Emission-Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18